Skip to main content
. 2018 Mar 30;8(3):e018180. doi: 10.1136/bmjopen-2017-018180

Figure 2.

Figure 2

Time trends in the prescription of anticoagulants in newly treated patients with atrial fibrilation between 2011 and 2015 in France (n=814 446). Significant change points in trends identified a segmented regression model. (a) Dabigatran reimbursement approval, (b) rivaroxaban reimbursement approval (c) and apixaban reimbursement approval, (d) security warning (risks of bleeding haemorrhages) from the national health agency, (e) downgrade of dabigatran reimbursement. DOACs, direct oral anticoagulants; VKA, vitamin K antagonist.